US drugmaker Eli Lilly plans to expand its research and development headquarters in Indianapolis, Indiana, to the tune of $70 million, adding floor space and a new disciplinary laboratory that will facilitate collaboration across multiple research functions.

The company said it expects to complete the expansion program by 2017. The new investment will further widen its footprint at its home base, where it spent $400 million two years ago to expand its insulin manufacturing capacity.